BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ketotransdel: Final Phase III data

Final data from the intent-to-treat (ITT) population (n=361) of a double-blind, U.S. Phase III trial showed that 1g thrice-daily topical Ketotransdel for 7 days missed the primary endpoint of significantly reducing pain intensity as measured by VAS scores from baseline to day 3 vs. placebo (p=0.087). In the modified ITT (mITT) population (n=326), which excluded 35 patients who did not meet study entry criteria...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >